Redhill Biopharma Ltd RDHL

Healthcare Drug Manufacturers - Specialty & Generic

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The compa...

NDAQ:RDHL - Post by User

Redhill Biopharma Ltd

<< Previous

Bullboard Posts

Next >>

(476)
•••

Post by Iseneschalon Jan 25, 2024 9:13am

111 Views

Post# 35844674

Ya want to know why Redhill sh price moved higher!!!!!!!

RedHill Biopharma Announces $8 Million Registered Direct Offering

2024-01-25 06:05 PT - News Release

Jan. 25, 2024

TEL AVIV, Israel and RALEIGH, N.C., Jan. 25, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 10,000,000 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, at a purchase price of $0.80 per ADS, in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 10,000,000 ADSs. The warrants will have an exercise price of $1.00 per ADS, will be immediately exercisable upon issuance and have a term of fiveyears following the issuance date. The closing of the offering is expected to occur on or about January 29, 2024, subject to the satisfaction of customary closing conditions